Floatz logo

REPAGLINIDE

Bariatric Surgery Candidate

University of Eastern FinlandSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

22 Active assets in the Bariatric Surgery Candidate cohort.

Asset / SponsorPhaseRating
LIDOCAINE
Instituto Mexicano del Seguro Social
Phase 4BBB
RAMIFENTANYL
Hospital dos Lusíadas
Phase 4BBB
Amoxicillin
Fatih Sultan Mehmet Training and Research Hospital
Phase 4BBB
Omeprazole
Fatih Sultan Mehmet Training and Research Hospital
Phase 4BB
Metformin
RenJi Hospital
Phase 4BB

View all 42 →

Same molecule, other indications

REPAGLINIDE is also rated in:

type 2 diabetes mellitusDormant
BB
Indicative ·
68 / 100
View asset →
diabetes mellitusDormant
BB
Indicative ·
66 / 100
View asset →
cystic fibrosisDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →